Challenges in pharmacokinetic modelling of [18F]fluoro-PEG-folate PET/CT imaging in epithelial ovarian cancer patients

Ruytenberg, T.; Ciggaar, I.A.; Peters, I.T.A.; Noortman, W.A.; Dibbets-Schneider, P.; Muynck, L.D.A.N. de; ... ; Geus-Oei, L.F. de (2024)

Article / Letter to editor

Purpose To describe the pharmacokinetic properties of the [ 18F]fuoro-polyethylene glycol(PEG)-folate radiotracer in PET/ CT imaging of patients with advanced stage epithelial ovarian cancer (EOC). Procedures In fve patients with advanced EOC (FIGO stage IIIB/IIIC, Fédération Internationale de Gynécologie et d’Obstétrique), a 90-min dynamic PET acquisition of the pelvis was performed directly after i.v. administration of 185 MBq [ 18F]fuoro-PEG6-folate. Arterial blood samples collected at nineteen timepoints were used to determine the plasma input function. A static volume of interest (VOI) for included tumor lesions was drawn manually on the PET images. Modelling was performed using PMOD software. Three diferent models (a 1-tissue compartment model (1T2k) and two 2-tissue compartment models, irreversible (2T3k) and reversible (2T4k)) were compared in goodness of ft with the time activity curves by means of the Akaike information criterion. Results The pharmacokinetic analysis in the pelvic area has proven to be much more challenging than expected. Only four out of 22 tumor lesions in fve patients were considered suitable to perform modelling on. The remaining tumor lesions were inapt due to either low tracer uptake, small size, proximity to other [ 18F]fuoro-PEG6-folate -avid structures and/or displacement by abdominal organ motion in the dynamic scan. Data from the four analyzed tumor lesions suggest that the irreversible 2T3k may best describe the pharmacokinetics. All 22 lesions were immunohistochemically stained positive for the folate receptor alpha (FRα) after resection. Conclusion Performing pharmacokinetic analysis in the abdominal pelvic region is very challenging. This brief article describes the challenges and pitfalls in pharmacokinetic analysis of a tracer with high physiological accumulation in the intestines, in case of lesions of limited size in the abdominal pelvic area.

• Molecular imaging
• Pharmacokinetic modeling
• Tracer kinetic methodology
• Dynamic PET
• PET tracers
• F-18
• Ovarian cancer

• All authors: Ruytenberg, T.; Ciggaar, I.A.; Peters, I.T.A.; Noortman, W.A.; Dibbets-Schneider, P.; Muynck, L.D.A.N. de; Kuil, J.; Kroon, C.D. de; Molenaar, T.J.M.; Helmerhorst, H.J.F.; Arias-Bouda, L.M.P.; Vahrmeijer, A.L.; Windhorst, A.D.; Velden, F.H.P. van; Gaarenstroom, K.N.; Geus-Oei, L.F. de
• Date: 2024-05-22
• Journal: Molecular Imaging and Biology
• DOI: doi:10.1007/s11307-024-01922-0